Document is current
Any future updates will be listed below
-
Authors
Templeman, Erin L.
Ferrat, Lauric A.
Parikh, Hemang M.
You, Lu
Triolo, Taylor M.
Steck, Andrea K.
Hagopian, William A.
Vehik, Kendra
Onengut-Gumuscu, Suna
Gottlieb, Peter A.
Rich, Stephen S.
Krischer, Jeffery P.
Redondo, Maria J.
Oram, Richard A.
,
-
Funding
Funding for this research was provided by:
Randox Laboratories
Juvenile Diabetes Research Foundation United Kingdom (3-SRA-2019-827-S-B, 3-SRA-2019-827-S-B)
National Institutes of Health (R01 DK121843, K23 DK136931, R01 DK121843, R01 DK121843, R01 DK121843, R01 DK121843, R01 DK121843, R01 DK121843, R01 DK121843)
- License Information
-
More Information
Article History
Received: 6 January 2025
Accepted: 17 June 2025
First Online: 21 July 2025
Declarations
:
: For TEDDY study, all procedures were approved by the ethics committees/institutional review boards including Colorado Multiple Institutional Review Board (04–0361); Medical College of Georgia Human Assurance Committee (2004–2010)/Georgia Health Sciences University Human Assurance Committee (2011–2012)/Georgia Regents University Institutional Review Board (2013–2017)/Augusta University Institutional Review Board (2017–present) (HAC 0405380); University of Florida Health Center Institutional Review Board (IRB201600277); Washington State Institutional Review Board (2004–2012)/Western Institutional Review Board (2013–present) (20130211); Ethics Committee of the Hospital District of Southwest Finland (Dnro168/2004); Bayerischen Landesärztekammer (Bavarian Medical Association) Ethics Committee (04089); and Regional Ethics Board in Lund, Sect. 2 (2004–2012)/Lund University Committee for Continuing Ethical Review (2013-present) (217/2004). In addition, TEDDY is monitored by an external evaluation committee formed by the National Institutes of Health, Bethesda, MD, USA.TrialNet Pathway to Prevention Clinical Trials.gov ID: NCT00097292 TN01 was/is approved by the Central IRB at the University of Miami. This approval began in 2016 with all sites completing the transition to the UM central IRB by the end of 2018 (per NIH requirements). Prior to then, each site had their own local approval.
: Not applicable.
: RAO has received consulting fees from Janssen R & D, and previously held a UK MRC Confidence in Concept grant to develop a 10 SNP type 1 diabetes GRS biochip with Randox R & D, and received research funding from Randox R & D. WAH has received consulting fees from Janssen R & D and Sanofi, and has received research funding from Sanofi. The remaining authors declare that they have no competing interests.
